Annolyse
BriefingsCompaniesInsightsPrinciplesCompareChatWatchlist

Explore

  • Briefings
  • Companies
  • Insights
  • Compare

Resources

  • Search
  • Methodology

© 2026 Annolyse.

Company archive

Ryman Healthcare (RYM) briefings

Read that company's published results in release order, newest first.

All briefingsConsumerHealthcareTransport & InfrastructurePrimary IndustriesPropertyInvestment CompaniesTechnologyConstruction & Materials
Open archive
Clear filters

Showing 1-7 of 7 published briefings.

Ryman Healthcare (RYM)•FY26•Released 26 May 2026

Free cash flow swings to +NZ$188m as EBITDAF nearly doubles

Operating momentum is real but Ryman remains loss-making at the PBT line, and the FCF swing is partly capex-driven rather than purely earnings-led.

Published 26 May 2026

Read briefing→
Ryman Healthcare (RYM)•HY26•Released 27 November 2025

PBT collapsed 123% to a NZ$40.2m loss as debt fell NZ$928m

Maiden NZ$56.2m FCF and the balance sheet reset frame the upside, but a NZ$152.7m receivables release flatters the cash result.

Published 21 April 2026

Read briefing→
Ryman Healthcare (RYM)•FY25•Released 29 May 2025

EBITDAF tripled to $45.5m but NPAT loss widened to -$436.8m

Operating recovery is overshadowed by a capex surge to 70.4% of revenue and a -$94.2m free cash outflow.

Published 28 April 2026

Read briefing→
Ryman Healthcare (RYM)•HY25•Released 28 November 2024

PBT up 21.9% but NPAT fell 49.4% on a tax-rate flip

A tax line that flipped from +30.2% to -46.0% drove the NPAT divergence while pre-lease free cash flow stayed below the historical range at -$52.5m.

Published 28 April 2026

Read briefing→
Ryman Healthcare (RYM)•HY24•Released 29 November 2023

Dividend suspended as FCF stays $158.4m negative, PBT falls 34%

Headline NPAT declines just 3.8% on a 30.2% tax credit, but underlying profit is flat and pre-lease cash flow sits well below the historical range.

Published 28 April 2026

Read briefing→
Ryman Healthcare (RYM)•HY23•Released 18 November 2022

NZ$281m working-capital build cut pre-lease FCF to NZ$51.8m as NPAT fell 31%

Underlying profit rose 44.8% but reported NPAT fell 31.1% as receivables expanded and capex jumped 56%, draining cash flow despite revenue growth.

Published 28 April 2026

Read briefing→
Ryman Healthcare (RYM)•FY22•Released 17 June 2022

Reported NPAT jumped 63.8% but underlying profit grew only 13.6%

Investment property revaluations drove the headline gain while capex at 55.9% of revenue absorbed most of the operating cash flow expansion.

Published 29 April 2026

Read briefing→

Get reporting-season briefings

Get full NZX result briefings by email as new coverage is published.